Cyclic GMP-dependent signaling in cardiac myocytes

Eiki Takimoto

Research output: Contribution to journalArticle

Abstract

Cyclic GMP (cGMP) and its effector kinase PKG regulate diverse cellular functions. In cardiac myocytes, cGMP is produced by soluble and particulate guanylyl cyclases (GCs), the former stimulated by nitric oxide and the latter by natriuretic peptides, and is hydrolyzed to inactive 5′-GMP by cGMP-phosphodiesterases (PDEs). cGMP-PKG modulates cardiac contractility, hypertrophy and remodeling, and exerts cardioprotection. Although early research efforts have mostly focused on cGMP synthetic pathways, recent studies have revealed that cGMP degradation controlled by PDEs plays a critical role in the physiological action of cGMP. Among several cGMP-PDEs, cGMPspecific PDE5 has been intensively investigated. Studies in experimental animal models and humans consistently demonstrate benefits from PDE5 inhibitors in various cardiac pathologies. Several clinical trials are ongoing or planned to test the efficacy of PDE5 inhibitors in human heart disease, including a large multicenter clinical trial (RELAX) led by the NIH evaluating sildenafil efficacy in heart failure with preserved ejection fraction. This review underscores the current understanding of cGMP-PKG signal regulation and its pathophysiological role in the heart, focusing on cardiac myocytes.

Original languageEnglish (US)
Pages (from-to)1819-1825
Number of pages7
JournalCirculation Journal
Volume76
Issue number8
DOIs
StatePublished - 2012

Fingerprint

Cyclic GMP
Cardiac Myocytes
Phosphoric Diester Hydrolases
Phosphodiesterase 5 Inhibitors
Clinical Trials
Guanosine Monophosphate
Natriuretic Peptides
Cardiomegaly
Multicenter Studies
Heart Diseases
Nitric Oxide
Phosphotransferases
Animal Models
Heart Failure
Pathology

Keywords

  • cGMP-dependent protein kinase
  • Cyclic GMP (cGMP)
  • Myocytes
  • Phosphodiesterases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cyclic GMP-dependent signaling in cardiac myocytes. / Takimoto, Eiki.

In: Circulation Journal, Vol. 76, No. 8, 2012, p. 1819-1825.

Research output: Contribution to journalArticle

Takimoto, Eiki. / Cyclic GMP-dependent signaling in cardiac myocytes. In: Circulation Journal. 2012 ; Vol. 76, No. 8. pp. 1819-1825.
@article{2581ae80f82f4b37953c589fbf1d7591,
title = "Cyclic GMP-dependent signaling in cardiac myocytes",
abstract = "Cyclic GMP (cGMP) and its effector kinase PKG regulate diverse cellular functions. In cardiac myocytes, cGMP is produced by soluble and particulate guanylyl cyclases (GCs), the former stimulated by nitric oxide and the latter by natriuretic peptides, and is hydrolyzed to inactive 5′-GMP by cGMP-phosphodiesterases (PDEs). cGMP-PKG modulates cardiac contractility, hypertrophy and remodeling, and exerts cardioprotection. Although early research efforts have mostly focused on cGMP synthetic pathways, recent studies have revealed that cGMP degradation controlled by PDEs plays a critical role in the physiological action of cGMP. Among several cGMP-PDEs, cGMPspecific PDE5 has been intensively investigated. Studies in experimental animal models and humans consistently demonstrate benefits from PDE5 inhibitors in various cardiac pathologies. Several clinical trials are ongoing or planned to test the efficacy of PDE5 inhibitors in human heart disease, including a large multicenter clinical trial (RELAX) led by the NIH evaluating sildenafil efficacy in heart failure with preserved ejection fraction. This review underscores the current understanding of cGMP-PKG signal regulation and its pathophysiological role in the heart, focusing on cardiac myocytes.",
keywords = "cGMP-dependent protein kinase, Cyclic GMP (cGMP), Myocytes, Phosphodiesterases",
author = "Eiki Takimoto",
year = "2012",
doi = "10.1253/circj.CJ-12-0664",
language = "English (US)",
volume = "76",
pages = "1819--1825",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "8",

}

TY - JOUR

T1 - Cyclic GMP-dependent signaling in cardiac myocytes

AU - Takimoto, Eiki

PY - 2012

Y1 - 2012

N2 - Cyclic GMP (cGMP) and its effector kinase PKG regulate diverse cellular functions. In cardiac myocytes, cGMP is produced by soluble and particulate guanylyl cyclases (GCs), the former stimulated by nitric oxide and the latter by natriuretic peptides, and is hydrolyzed to inactive 5′-GMP by cGMP-phosphodiesterases (PDEs). cGMP-PKG modulates cardiac contractility, hypertrophy and remodeling, and exerts cardioprotection. Although early research efforts have mostly focused on cGMP synthetic pathways, recent studies have revealed that cGMP degradation controlled by PDEs plays a critical role in the physiological action of cGMP. Among several cGMP-PDEs, cGMPspecific PDE5 has been intensively investigated. Studies in experimental animal models and humans consistently demonstrate benefits from PDE5 inhibitors in various cardiac pathologies. Several clinical trials are ongoing or planned to test the efficacy of PDE5 inhibitors in human heart disease, including a large multicenter clinical trial (RELAX) led by the NIH evaluating sildenafil efficacy in heart failure with preserved ejection fraction. This review underscores the current understanding of cGMP-PKG signal regulation and its pathophysiological role in the heart, focusing on cardiac myocytes.

AB - Cyclic GMP (cGMP) and its effector kinase PKG regulate diverse cellular functions. In cardiac myocytes, cGMP is produced by soluble and particulate guanylyl cyclases (GCs), the former stimulated by nitric oxide and the latter by natriuretic peptides, and is hydrolyzed to inactive 5′-GMP by cGMP-phosphodiesterases (PDEs). cGMP-PKG modulates cardiac contractility, hypertrophy and remodeling, and exerts cardioprotection. Although early research efforts have mostly focused on cGMP synthetic pathways, recent studies have revealed that cGMP degradation controlled by PDEs plays a critical role in the physiological action of cGMP. Among several cGMP-PDEs, cGMPspecific PDE5 has been intensively investigated. Studies in experimental animal models and humans consistently demonstrate benefits from PDE5 inhibitors in various cardiac pathologies. Several clinical trials are ongoing or planned to test the efficacy of PDE5 inhibitors in human heart disease, including a large multicenter clinical trial (RELAX) led by the NIH evaluating sildenafil efficacy in heart failure with preserved ejection fraction. This review underscores the current understanding of cGMP-PKG signal regulation and its pathophysiological role in the heart, focusing on cardiac myocytes.

KW - cGMP-dependent protein kinase

KW - Cyclic GMP (cGMP)

KW - Myocytes

KW - Phosphodiesterases

UR - http://www.scopus.com/inward/record.url?scp=84864386275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864386275&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-12-0664

DO - 10.1253/circj.CJ-12-0664

M3 - Article

C2 - 22785374

AN - SCOPUS:84864386275

VL - 76

SP - 1819

EP - 1825

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 8

ER -